Facebook
Twitter
LinkedIn
Forward2024 Recorded Symposium Session: Semaglutide for Weight Loss: The RDN’s Role
This presentation will explore semaglutides, which belong to a class of medications known as glucagonlike peptide-1 (GLP-1) receptor agonists (sold as Wegovy, Ozempic, and Rybelsus). In addition to a valuable overview of these important and widely popular medications, Escobar will discuss their mechanisms of action, nutrition recommendations for patients on these medications, and strategies to manage common side effects.
Additional Information
Su-Nui Escobar, DCN, RDN, FAND, is an RD nutritionist with extensive and up-to-date knowledge of weight management. She obtained her doctoral degree in clinical nutrition from the University of North Florida, and works as an RD studying the evaluation of weight loss medications. She has served as a spokesperson for the Academy of Nutrition and Dietetics, and writes extensively about nutrition, particularly in relation to weight loss medications.
Su-Nui Escobar, faculty for this educational event, is a consultant for South Broward Research.
All of the relevant financial relationships listed for these individuals have been mitigated.
An “ineligible company” includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products use by or on patients.
In support of improving patient care, Great Valley Publishing Company is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity will also award credit for dietetics (CDR CPEU).
RDs and DTRs are to select activity type 102 in their Activity Log. Sphere and Competency selection is at the learner’s discretion.
Available Credit
- 1.00 CDR